PT-141 (Bremelanotide) vs FGL
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →FGL
FGL (FG Loop) is a synthetic peptide that mimics the neural cell adhesion molecule (NCAM) FG loop region. It promotes neuroplasticity and has shown cognitive-enhancing effects in research.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | FGL |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Binds to FGFR1 (fibroblast growth factor receptor 1) to activate downstream signaling cascades that promote neurite outgrowth, synaptic plasticity, and neuronal survival. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Research protocols have used subcutaneous doses ranging from 1-10mg. Intranasal administration also studied. Optimal dosing not established. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Subcutaneous injection or intranasal administration. Research compound with limited human dosing data. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Limited human data available. Animal studies show good tolerability. |
| Best For |